Cargando…

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer

Background: Breast cancer is the most common malignancy, and approximately 70% of breast cancers are estrogen receptor-α (ERα) positive. The anti-estrogen tamoxifen is a highly effective and commonly used treatment for patients with ER+ breast cancer. However, 30% of breast cancer patients fail adju...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shu-Shu, Li, Yun, Zhang, Hui, Zhang, Di, Zhang, Xiao-Bei, Wang, Xin, Yu, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482812/ https://www.ncbi.nlm.nih.gov/pubmed/32929377 http://dx.doi.org/10.7150/thno.46297

Ejemplares similares

Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer
por: Zheng, Zao-zao, et al.
Publicado: (2022)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells
por: Zhang, XianTian, et al.
Publicado: (2010)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells
por: Zhang, Xiumei, et al.
Publicado: (2019)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

Downregulation of miR-575 Inhibits the Tumorigenesis of Gallbladder Cancer via Targeting p27 Kip1
por: Qin, Yiyu, et al.
Publicado: (2020)

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
por: Li, Yuanyuan, et al.
Publicado: (2017)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

YAP inhibits ERα and ER(+) breast cancer growth by disrupting a TEAD-ERα signaling axis
por: Li, Xu, et al.
Publicado: (2022)

Paeoniflorin Enhances the Sensitivity of ER-Positive Breast Cancer Cells to Tamoxifen through Promoting Sirtuin 4
por: Zhang, Pei, et al.
Publicado: (2022)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Shrimp miR-965 induced the human melanoma stem-like cell apoptosis and inhibited their stemness by disrupting the MCL-1-ER stress-XBP1 feedback loop in a cross-species manner
por: Wu, Wenlin, et al.
Publicado: (2020)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
por: Zhang, Xia, et al.
Publicado: (2015)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Z-ligustilide restores tamoxifen sensitivity of ERα negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERα
por: Ma, Hui, et al.
Publicado: (2017)

Downregulation of miR-575 Inhibits the Tumorigenesis of Gallbladder Cancer via Targeting P27 Kip1 [Corrigendum]
Publicado: (2020)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: Perez White, Bethany, et al.
Publicado: (2013)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

MED16 Promotes Tumour Progression and Tamoxifen Sensitivity by Modulating Autophagy through the mTOR Signalling Pathway in ER-Positive Breast Cancer
por: Li, Han, et al.
Publicado: (2022)

A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia
por: He, Weili, et al.
Publicado: (2023)

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
por: Ma, Ji, et al.
Publicado: (2014)

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
por: Turczyk, Lukasz, et al.
Publicado: (2017)

Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
por: Vafeiadou, Vasiliki, et al.
Publicado: (2022)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
por: Lin, Sheng-Li, et al.
Publicado: (2010)

FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis
por: Xu, Lu, et al.
Publicado: (2021)

Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer
por: Chen, Rui, et al.
Publicado: (2020)

ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization
por: Wrobel, Kinga, et al.
Publicado: (2016)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
por: Cizeron-Clairac, Geraldine, et al.
Publicado: (2015)

miR-1271 inhibits ERα expression and confers letrozole resistance in breast cancer
por: Yu, Tao, et al.
Publicado: (2017)

Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4
por: Ahmad, Aamir, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hrbab05clic0lsjr0jud2id9hn